395 related articles for article (PubMed ID: 32884236)
1. Assessment of a New Ginsenoside Rh2 Nanoniosomal Formulation for Enhanced Antitumor Efficacy on Prostate Cancer: An in vitro Study.
Zare-Zardini H; Alemi A; Taheri-Kafrani A; Hosseini SA; Soltaninejad H; Hamidieh AA; Haghi Karamallah M; Farrokhifar M; Farrokhifar M
Drug Des Devel Ther; 2020; 14():3315-3324. PubMed ID: 32884236
[TBL] [Abstract][Full Text] [Related]
2. Enhanced nuclear translocation and activation of aryl hydrocarbon receptor (AhR) in THP-1 monocytic cell line by a novel niosomal formulation of indole-3-carbinol.
Abbaspour Sani N; Hasani M; Kianmehr A; Mohammadi S; Sheikh Arabi M; Yazdani Y
J Liposome Res; 2020 Jun; 30(2):117-125. PubMed ID: 30917715
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy.
Alemi A; Zavar Reza J; Haghiralsadat F; Zarei Jaliani H; Haghi Karamallah M; Hosseini SA; Haghi Karamallah S
J Nanobiotechnology; 2018 Mar; 16(1):28. PubMed ID: 29571289
[TBL] [Abstract][Full Text] [Related]
4. Utilization of green formulation technique and efficacy estimation on cell line studies for dual anticancer drug therapy with niosomes.
Khan DH; Bashir S; Correia A; Khan MI; Figueiredo P; Santos HA; Peltonen L
Int J Pharm; 2019 Dec; 572():118764. PubMed ID: 31628977
[TBL] [Abstract][Full Text] [Related]
5. Glucosamine anchored cancer targeted nano-vesicular drug delivery system of doxorubicin.
Pawar S; Vavia P
J Drug Target; 2016; 24(1):68-79. PubMed ID: 26152812
[TBL] [Abstract][Full Text] [Related]
6. Evaluation the Anti-Cancer Effect of PEGylated Nano-Niosomal Gingerol, on Breast Cancer Cell lines (T47D), In-Vitro.
Behroozeh A; Mazloumi Tabrizi M; Kazemi SM; Choupani E; Kabiri N; Ilbeigi D; Heidari Nasab A; Akbarzadeh Khiyavi A; Seif Kurdi A
Asian Pac J Cancer Prev; 2018 Mar; 19(3):645-648. PubMed ID: 29580033
[TBL] [Abstract][Full Text] [Related]
7. Stereospecificity of hydroxyl group at C-20 in antiproliferative action of ginsenoside Rh2 on prostate cancer cells.
Liu J; Shimizu K; Yu H; Zhang C; Jin F; Kondo R
Fitoterapia; 2010 Oct; 81(7):902-5. PubMed ID: 20554003
[TBL] [Abstract][Full Text] [Related]
8. Lawsone-loaded Niosome and its antitumor activity in MCF-7 breast Cancer cell line: a Nano-herbal treatment for Cancer.
Barani M; Mirzaei M; Torkzadeh-Mahani M; Nematollahi MH
Daru; 2018 Sep; 26(1):11-17. PubMed ID: 30159762
[TBL] [Abstract][Full Text] [Related]
9. Anticancer property of ginsenoside Rh2 from ginseng.
Li X; Chu S; Lin M; Gao Y; Liu Y; Yang S; Zhou X; Zhang Y; Hu Y; Wang H; Chen N
Eur J Med Chem; 2020 Oct; 203():112627. PubMed ID: 32702586
[TBL] [Abstract][Full Text] [Related]
10. Novel multicore niosomes based on double pH-sensitive mixed micelles for Ginsenoside Rh2 delivery.
Chen D; Yu H; Mu H; Li G; Shen Y
Artif Cells Nanomed Biotechnol; 2014 Jun; 42(3):205-9. PubMed ID: 24823243
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of curcumin-Cu and curcumin-Ag nanoparticle loaded niosome: Enhanced antibacterial and anti-biofilm activities.
Targhi AA; Moammeri A; Jamshidifar E; Abbaspour K; Sadeghi S; Lamakani L; Akbarzadeh I
Bioorg Chem; 2021 Oct; 115():105116. PubMed ID: 34333420
[TBL] [Abstract][Full Text] [Related]
12. Novel ginsenoside-based multifunctional liposomal delivery system for combination therapy of gastric cancer.
Hong C; Wang D; Liang J; Guo Y; Zhu Y; Xia J; Qin J; Zhan H; Wang J
Theranostics; 2019; 9(15):4437-4449. PubMed ID: 31285771
[TBL] [Abstract][Full Text] [Related]
13. 1α,25-Dihydroxyvitamin D
Ben-Eltriki M; Deb S; Guns EST
J Steroid Biochem Mol Biol; 2021 May; 209():105828. PubMed ID: 33493594
[TBL] [Abstract][Full Text] [Related]
14. Encapsulation of Leflunomide (LFD) in a novel niosomal formulation facilitated its delivery to THP-1 monocytic cells and enhanced Aryl hydrocarbon receptor (AhR) nuclear translocation and activation.
Hasani M; Sani NA; Khodabakhshi B; Arabi MS; Mohammadi S; Yazdani Y
Daru; 2019 Dec; 27(2):635-644. PubMed ID: 31432467
[TBL] [Abstract][Full Text] [Related]
15. Niosomal delivery of simvastatin to MDA-MB-231 cancer cells.
Akbarzadeh I; Saremi Poor A; Yaghmaei S; Norouzian D; Noorbazargan H; Saffar S; Ahangari Cohan R; Bakhshandeh H
Drug Dev Ind Pharm; 2020 Sep; 46(9):1535-1549. PubMed ID: 32808813
[TBL] [Abstract][Full Text] [Related]
16. In vitro Characterization and Release Studies of Combined Nonionic Surfactant-Based Vesicles for the Prolonged Delivery of an Immunosuppressant Model Drug.
Rasul A; Imran Khan M; Ur Rehman M; Abbas G; Aslam N; Ahmad S; Abbas K; Akhtar Shah P; Iqbal M; Ahmed Al Subari AM; Shaheer T; Shah S
Int J Nanomedicine; 2020; 15():7937-7949. PubMed ID: 33116510
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of a novel cationic PEGylated niosome-encapsulated forms of doxorubicin, quercetin and siRNA for the treatment of cancer by using combination therapy.
Hemati M; Haghiralsadat F; Yazdian F; Jafari F; Moradi A; Malekpour-Dehkordi Z
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1295-1311. PubMed ID: 30033768
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases.
Cosco D; Paolino D; Cilurzo F; Casale F; Fresta M
Int J Pharm; 2012 Jan; 422(1-2):229-37. PubMed ID: 22093954
[TBL] [Abstract][Full Text] [Related]
19. Preparation, physicochemical properties, in vitro evaluation and release behavior of cephalexin-loaded niosomes.
Ghafelehbashi R; Akbarzadeh I; Tavakkoli Yaraki M; Lajevardi A; Fatemizadeh M; Heidarpoor Saremi L
Int J Pharm; 2019 Oct; 569():118580. PubMed ID: 31374239
[TBL] [Abstract][Full Text] [Related]
20. Development of Niosomal Vesicles Loaded Mometasone Furoate Gel for Transdermal Delivery and its Evaluation.
Rane BR; Chavan PY; Kate NS; Jain AS
Recent Adv Drug Deliv Formul; 2023; 17(4):300-313. PubMed ID: 37974444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
